A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice
Launched by UNIVERSITY OF COPENHAGEN · Dec 20, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to improve the way doctors use prostate-specific antigen (PSA) tests, which are used to help detect prostate cancer. While PSA tests can be useful, they can also sometimes give false alarms, leading to unnecessary worry and treatment. The study aims to help general practitioners better understand when and how to use these tests based on the latest evidence, ensuring they only recommend them to the right patients.
To participate in this trial, quality clusters—groups of doctors working together—need to have a coordinator and be open to having a meeting focused on PSA testing in 2025. The trial is currently recruiting participants and is open to all genders. If selected, participants can expect to engage in discussions and training that will help improve their knowledge and practice regarding PSA testing. This is a great opportunity for doctors to enhance their skills and provide better care for their patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Quality clusters with a cluster coordinator
- • Quality clusters willing to participate in a cluster meeting with PSA as a theme in 2025.
- Exclusion Criteria:
- • Quality clusters who already planned their cluster meetings in 2025.
- • Quality clusters unwilling to await allocation before planning their cluster meetings in 2025.
- • Quality clusters participating in the pilot study
About University Of Copenhagen
The University of Copenhagen, a leading research institution in Denmark, is dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including health sciences, pharmacology, and biotechnology, to design and conduct rigorous clinical studies. Committed to ethical standards and scientific integrity, the University of Copenhagen aims to contribute significantly to the global medical community by facilitating groundbreaking research that addresses pressing healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Marius Brostrøm Kousgaard, Associate professor
Principal Investigator
Center of General Practice, Department of Public Health, University of Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported